Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice

In the PARADIGM-HF trial, the novel drug LCZ696 is more effective than enalapril for heart failure; Gerasimos Filippatos et al discuss the clinical applications and highlight the PARAGON-HF trial that is addressing the effect of LCZ696 in patient subgroups.

Source: BMC Medicine - February 18, 2015 Category: Internal Medicine Authors: Gerasimos FilippatosDimitrios FarmakisJohn ParissisJohn Lekakis Source Type: research